Fedratinib Approved for Myelofibrosis

​ The FDA has now approved fedratinib (Inrebic®, Impact Biomedicines, Inc./Celgene Corporation) for the treatment of intermediate-2 or high-risk primary or secondary myelofibrosis. A myeloproliferative neoplasm, myelofibrosis can either present as a primary condition or as a secondary condition following the transformation of polycythemia vera or essential thrombocythemia. Myelofibrosis causes anemia, splenomegaly, and debilitating symptoms, and it shortens survival. "Prior to today, there was o...
Continue reading

Utilizing Proper Supportive Care in Multiple Myeloma: An Interview With Smith Giri, MD, MHS

​ In the treatment of multiple myeloma, supportive care is essential to mitigating the risks of infection and bone disease. However, a study published recently in Cancer by Smith Giri, MD, MHS, and colleagues found that guideline-recommended supportive care measures are underutilized in older patients with multiple myeloma. In this interview with i3 Health, Dr. Giri discusses supportive care for patients with myeloma, as well as interventions that could increase the use of these measures. Can yo...
Continue reading

Under Medicare, CAR T-Cell Therapy Now Available Nationwide

The Centers for Medicare & Medicaid Services (CMS) have finalized nationwide coverage of chimeric antigen receptor (CAR) T-cell therapy, replacing the previous policy under which the decision of treatment coverage was left to Medicare's regional administrators. "As the first type of FDA-approved gene therapy, CAR T-cell therapies are an important scientific advancement in this promising new area of medicine and provide treatment options for some patients who had nowhere else to turn," c...
Continue reading

Older Patients with Myeloma: Supportive Care Underutilized

​ Several facets of supportive care are important in multiple myeloma, including management of bone disease, thromboprophylaxis, and prevention of infectious disease. Appropriate supportive care measures have been outlined in well-established guidelines, but a new study reports that often, these are not followed. For this study, which has been published in Cancer , the researchers focused on three outcomes regarding guideline-recommended supportive care: the use of bone-modifying drugs (BMDs) wi...
Continue reading

Parthenolide, a Flowering Plant Compound, Could Fight CLL

Parthenolide, a compound derived from feverfew, a common garden plant, has the potential to provide an alternative treatment for chronic lymphocytic leukemia (CLL). The most common adult leukemia, CLL typically affects patients over the age of 60, many of whom have comorbidities that prevent the use of aggressive chemotherapy. Additionally, because the disease eventually becomes resistant to treatment in some patients, there is a need to develop alternative, less aggressive treatment options. Re...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.